

| 000 -LEADER | |
|---|---|
| fixed length control field | 03114nam a2200145Ia 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260209120143.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 260209s9999||||xx |||||||||||||| ||und|| |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Nivedita Singh |
| 245 #0 - TITLE STATEMENT | |
| Title | Patent and competition interface through the prism of pharmaceutical sector : a comparative approach of US, EU and India |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | BangaloreBangalore |
| Name of publisher, distributor, etc. | NLSIU |
| Date of publication, distribution, etc. | 2020 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 91 p. ; 25 cm. |
| 505 ## - FORMATTED CONTENTS NOTE | |
| Formatted contents note | TABLE OF CONTENTS ACKNOWLEDGEMENT ; ABBREVIATIONS ; LIST OF CASES ; CHAPTER 1 ; INTRODUCTION ; CHAPTER 2 ; COMPETITION & ANTI-TRUST ISSUES IN THE PHARMACEUTICAL INDUSTRY WITHIN US ; 2.1 LEGAL FRAMEWORK OF ANTI-TRUST LAWS ; 2.2 PATENT LINKAGE SYSTEM IN US: REVISITING HATCH WAXMAN ACT ; THE GENERIC INCENTIVES ; THE INNOVATOR INCENTIVES ; 2.3 TYPE OF ANTI-TRUST CASES LEADING TO INTERFACE IN THE PHARMACEUTICAL INDUSTRY ; 2.3.1 CASES OF MONOPOLIZATION ; 2.3.2 THE INNOVATOR MARKET DOCTRINE & MERGERS ; 2.3.3 MERGERS IN THE PHARMACEUTICAL INDUSTRY ; 2.3.4 POTENTIAL COMPETITION MERGERS ; 2.4 THE EVERGREENING DEBATE IN US ; 2.5 PRODUCT HOPPING; 2.5.1 STANCE ON PRODUCT HOPPING ; 2.6 AGREEMENTS NOT TO COMPETE: PAY FOR DELAY ; 2.7 CONCLUSIONS & IMPLICATION ON DEVELOPING & LEAST DEVELOPED COUNTRIES ; CHAPTER 3 ; PHARMACEUTICAL BUSINESS STRATEGIES: COMPETITION BETWEEN ORIGINATOR & GENERIC COMPANIES WITHIN EU ; 3.1 PATENT LINKAGE SYSTEM IN EU ; 3.2 EUROPEAN PATENT SYSTEM: REQUIREMENTS FOR PATENTABILITY ; 3.3 EUROPEAN PATENT CONVENTION ; 3.4 PATENTABILITY REQUIREMENTS ; 3.4.1 TECHNICAL CHARACTER ; 3.4.2 NOVELTY ; 3.4.3 INVENTIVE STEP ; 3.4.4. INDUSTRIAL APPLICABILITY ; 3.5 SUPPLEMENTARY PROTECTION CERTIFICATE ; 3.6 COMPETITION LAW IN EU ; 3.6.1 THE CONCEPT OF ABUSE OF DOMINANT & MONOPOLY POSITION ; 3.6.2 DOMINANCE OF AN UNDERTAKING WITHIN THE SUBSTANTIAL PART OF THE MARKET ; 3.6.3 WHAT CONSTITUTES ABUSE OF DOMINANCE ; 3.7 APPLIED PATENT STRATEGIES DURING THE DRUG LIFE CYCLE BY THE INNOVATORS & COMPETITION INTERFACE ; 3.7.1 SECOND GENERATION OR FOLLOW ON DRUGS & INFLUENCING MEDICAL FRATERNITY ; 3.7.2 PATENT CLUSTERS ; 3.7.3 DIVISIONAL PATENT APPLICATION ; 3.7.4 PATENT LITIGATION ; 3.7.5. DEVELOPMENT OF PATENT PORTFOLIO ; 3.8 THE ASTRAZENECA CASE ; 3.9 CONCLUSIVE ANALYSIS OF JUDGMENT ; 3.10 CONCLUSION OF STRATEGIES LEGALITY ; CHAPTER 4 ; DETERMINATION OF ANTI COMPETITIVE PRACTICES REGARDING PATENT ABUSE & PATENT LINKAGE SYSTEM IN INDIA ; 4.1 THE STANCE OF INDIAN JUDICIARY ON THE INTRODUCTION OF PATENT LINKAGE SYSTEM IN INDIA ; 4.2 PATENT EVERGREENING ; 4.3 IMPORTANCE OF RESEARCH & DEVELOPMENT FOR DYNAMIC PHARMACEUTICAL INDUSTRY ; 4.4 LEGAL FRAMEWORK ON RIGHT TO HEALTH & ACCESS TO MEDICINES ; 4.4.1 CONTOURS OF RIGHT TO HEALTH IN INDIA ; 4.4.2 TRIPS PERSPECTIVE OF PATENT SYSTEM & ESSENTIAL MEDICINES; 4.5 INDIAN APPROACH TO COMPETITION LAW & PHARMACEUTICAL INVENTIONS ; 4.6 COMPARATIVE ANALYSIS OF US, EU & INDIA ; 4.7 CONCLUSION ; CHAPTER 5 ; CONCLUSION & SUGGESTIONS ; BIBLIOGRAPHY . |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Prof. (Dr.) T. Ramakrishna - GuideProf. (Dr.) T. Ramakrishna - Guide |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://dans.nls.ac.in/handle/123456789/414">https://dans.nls.ac.in/handle/123456789/414</a> |
| Withdrawn status | Lost status | Damaged status | Not for loan | Home library | Current library | Date acquired | Total Checkouts | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | 09.02.2026 | LLM830 | 09.02.2026 | 09.02.2026 | Dissertation |